Aurinia Pharmaceuticals Inc. (AUPH)

5.15 +0.03 (+0.59%) At close: 04:00PM EDT

Aurinia Pharmaceuticals Inc.

118 Avenue , 14315
Suite 140
Edmonton, AB T5L 4S6
Canada
250 744 2487
https://www.auriniapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 300

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Peter S. Greenleaf M.B.A.	President, CEO & Director	1.57M	N/A	1970
Mr. Matthew Maxwell Donley M.B.A.	Executive Vice President of Operations & Strategy	901.84k	N/A	1969
Mr. Stephen P. Robertson	Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer	836.38k	N/A	1982

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Corporate governance

Aurinia Pharmaceuticals Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.